Search results
Results From The WOW.Com Content Network
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...
Prior FTC inquiry. Friday’s action comes a little more than two months after the FTC published a scathing interim report on the PBM industry that followed a two-year inquiry. It detailed how ...
The FTC sued the three PBMs in September, accusing them of steering diabetes patients toward higher priced insulin products in order to reap millions of dollars in rebates from drugmakers.
On Tuesday, the FTC issued an interim report, saying the three biggest middlemen - managing 79% of U.S. prescription drug claims - have used years of dealmaking to gain outsized influence on drug ...
OptumRx, the group's pharmacy benefit manager, along with its two main peers, Express Scripts and CVS Caremark Rx, have pocketed an extra $7.3 billion over cost thanks to price gouging, according ...
The lawsuit asks a federal judge in St. Louis, Missouri to order the FTC to take the report down and recuse Chair Lina Khan from any actions pertaining to the company, which is owned by Cigna Corp.
The FTC says it has evidence PBMs and drug manufacturers "sometimes enter rebate agreements expressly conditioned on excluding [lower cost] generic drugs from coverage," according to the report.
The FTC found that 22 percent of specialty drugs dispensed by PBM-affiliated pharmacies were marked up by more than 1,000 percent while 41 percent were marked up between 100 and 1,000 percent.